CCP
RIGL icon

Corient Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Corient Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,326
Closed -$40K – 747
2022
Q1 		$40K Buy
+1,326
New +$35.9K ﹤0.01% 734

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Capital Partners's RIGL Position: Q2 2022 in Review

Corient Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 1,326 shares — an estimated $40K sold.

Corient Capital Partners first reported a position in RIGL in Q1 2022 and held it in 1 quarter. The position peaked at $40K in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Corient Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Corient Capital Partners sold 1,326 Rigel Pharmaceuticals shares in Q2 2022, an estimated $40K.
  • Corient Capital Partners first reported a position in Rigel Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Corient Capital Partners's Rigel Pharmaceuticals position peaked at $40K in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.